NCT03183024View on ClinicalTrials.gov

Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody

PHASE4CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 12, 2017

Primary Completion Date

November 6, 2018

Study Completion Date

November 6, 2018

Conditions
Chronic Idiopathic Urticaria
Interventions
BIOLOGICAL

benralizumab

open-label treatment

BIOLOGICAL

placebo

sterile water to mimic benralizumab

Trial Locations (1)

45231

Bernstein Clinical Research Center, Cincinnati

All Listed Sponsors
lead

Jonathan A. Bernstein, MD

OTHER

NCT03183024 - Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody | Biotech Hunter | Biotech Hunter